Q4 Earnings Forecast for CervoMed Issued By HC Wainwright

CervoMed Inc. (NASDAQ:CRVO) – Stock analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for CervoMed in a research report issued on Thursday, December 5th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.53) for the quarter. HC Wainwright has a “Buy” rating and a $42.00 price target on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for CervoMed’s Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.68) EPS and Q4 2025 earnings at ($0.87) EPS.

CervoMed (NASDAQ:CRVO) last released its earnings results on Tuesday, November 12th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.14). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The company had revenue of $1.94 million for the quarter, compared to the consensus estimate of $1.75 million.

Other equities analysts have also recently issued reports about the stock. D. Boral Capital reaffirmed a “buy” rating and set a $34.00 price target on shares of CervoMed in a research note on Wednesday, November 27th. Chardan Capital reissued a “buy” rating and issued a $55.00 price objective on shares of CervoMed in a research note on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, CervoMed currently has an average rating of “Buy” and a consensus target price of $49.14.

CervoMed Stock Up 0.2 %

NASDAQ CRVO opened at $9.72 on Friday. CervoMed has a 52 week low of $5.85 and a 52 week high of $26.38. The company has a fifty day moving average of $12.14 and a two-hundred day moving average of $15.14.

Institutional Trading of CervoMed

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC increased its holdings in CervoMed by 5.2% during the 2nd quarter. Renaissance Technologies LLC now owns 32,333 shares of the company’s stock worth $554,000 after purchasing an additional 1,600 shares during the period. Fred Alger Management LLC purchased a new position in shares of CervoMed during the second quarter valued at $60,000. Citizens Financial Group Inc. RI increased its stake in shares of CervoMed by 13.2% during the third quarter. Citizens Financial Group Inc. RI now owns 30,509 shares of the company’s stock valued at $445,000 after buying an additional 3,553 shares during the period. FMR LLC bought a new stake in shares of CervoMed in the third quarter valued at about $56,000. Finally, Rhumbline Advisers purchased a new stake in CervoMed in the second quarter worth about $96,000. Institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.